Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC

Sonja Althammer, PhD
Published: Wednesday, Nov 16, 2016


Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.  
 
It was already known that PD-L1 by itself serves as biomarker to predict response to durvalumab.  However, researchers hypothesized that both CD8+ and PD-L1+ cells were critical for patient response to immunotherapies.
 
The study determined that the combination of CD8+ and PD-L1+ both correlated with response and improved overall survival with durvalumab. An independent study is planned to validate these results.
 
SELECTED
LANGUAGE

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.  
 
It was already known that PD-L1 by itself serves as biomarker to predict response to durvalumab.  However, researchers hypothesized that both CD8+ and PD-L1+ cells were critical for patient response to immunotherapies.
 
The study determined that the combination of CD8+ and PD-L1+ both correlated with response and improved overall survival with durvalumab. An independent study is planned to validate these results.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x